FrancophonIA/ELRC3.0 huggingface dataset:
English: Jentadueto is used in adults with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Danish: Jentadueto anvendes til behandling af voksne patienter med type 2-sukkersyge til at forbedre reguleringen af blodsukkeret.
English: The study looking at linagliptin in combination with metformin and insulin showed that this combination was more effective than the combination of insulin and metformin at reducing HbA1c levels (reduction of 0.77 percentage points was seen with linagliptin compared with a reduction of 0.10 percentage points with placebo).
Danish: Undersøgelsen af linagliptin i kombination med metformin og insulin viste, at denne kombination var mere effektiv end kombinationen af insulin og metformin til at sænke mængden af HbA1c (linagliptin medførte en reduktion på 0,77 procentpoint sammenlignet med en reduktion på 0,10 procentpoint med placebo).
English: A further study was carried out involving 491 patients with type 2 diabetes taking metformin twice per day, where placebo or linagliptin at either 2.5 mg twice per day or at 5 mg once per day was added to their treatment.
Danish: Der blev udført endnu en undersøgelse af 491 patienter med type 2-sukkersyge, hvor behandlingen med metformin to gange dagligt blev suppleret med placebo eller linagliptin i en dosis på enten 2,5 mg to gange dagligt eller 5 mg én gang dagligt.
English: What is Jentadueto?
Danish: Hvad er Jentadueto?
English: What is Jentadueto used for?
Danish: Hvad anvendes Jentadueto til?
English: How has Jentadueto been studied?
Danish: Hvordan blev Jentadueto undersøgt?
English: Another study was carried out involving 791 patients with type 2 diabetes, where the combination of linagliptin plus metformin given twice per day was compared with giving metformin alone, linagliptin alone or placebo.
Danish: I en anden undersøgelse med 791 patienter med type 2-sukkersyge blev kombinationen linagliptin plus metformin to gange dagligt sammenlignet med metformin alene, linagliptin alene og placebo.
English: The study with the combination of linagliptin and metformin showed that it was more effective than linagliptin or metformin alone, as well as placebo, at reducing HbA1c levels.
Danish: Undersøgelsen med kombinationen af linagliptin og metformin viste, at kombinationen er mere effektiv end linagliptin eller metformin alene og mere effektiv end placebo til at nedsætte mængden af HbA1c.
English: What benefit has Jentadueto shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Jentadueto?
English: The CHMP concluded that the combination of linagliptin and metformin has been shown to be effective at lowering HbA1c levels, and that linagliptin 2.5 mg twice per day was as effective as 5 mg once per day, which is approved in the EU for use on its own and in combination with metformin and with metformin plus a sulphonylurea or insulin.
Danish: CHMP konkluderede, at kombinationen af linagliptin og metformin har vist sig at være effektiv til at sænke mængden af HbA1c, og at linagliptin 2,5 mg to gange dagligt er lige så effektivt som 5 mg én gang dagligt.
English: The company presented the results of four studies with linagliptin in patients with type 2 diabetes, which were used to support the approval of Trajenta in the EU, comparing linagliptin given at 5 mg once per day with placebo (a dummy treatment).
Danish: Undersøgelserne blev anvendt til støtte for godkendelsen af Trajenta i EU og sammenlignede linagliptin, 5 mg én gang dagligt, med placebo (en virkningsløs behandling).
English: How is Jentadueto used?
Danish: Hvordan anvendes Jentadueto?
English: By prolonging the action of incretin hormones in the blood, linagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Danish: Det får bugspytkirtlen til at producere mere insulin, når blodsukkeret er højt.
English: How does Jentadueto work?
Danish: Hvordan virker Jentadueto?
English: When given in combination, linagliptin with metformin gave a reduction of 0.56 points compared with a rise of 0.10 points; linagliptin with metformin plus a sulphonylurea gave a reduction of 0.72 points compared with 0.10 points.
Danish: Når linagliptin blev anvendt sammen med metformin plus et sulfonylurinstof, gav det en reduktion på 0,72 point, sammenholdt med 0,10 point.
English: 9 September 2014 EMA/554928/2014
Danish: Den 9. september 2014 EMA/554928/2014
English: Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001446.jsp&mid =WC0b01ac058004d5c1
Danish: Tilgængelig på: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001446.jsp&mid=WC 0b01ac058004d5c1
English: The review of RAS-acting agents was initiated at the request of the Italian Medicines Agency (AIFA), under Article 31 of Directive 2001/83/EC.
Danish: Gennemgangen af RAS-aktive lægemidler blev indledt på anmodning af den italienske lægemiddelstyrelse (AIFA) i medfør af artikel 31 i direktiv 2001/83/EF.
English: • Patients currently taking a combination of these medicines, or who have any concerns or questions, should discuss their medication with their doctor at their next regular appointment.
Danish: • Patienter, der på nuværende tidspunkt får en kombination af disse lægemidler, eller som har betænkeligheder eller spørgsmål, skal drøfte deres behandling med lægen ved næste planlagte besøg.
English: Restriction of combined use of medicines affecting the renin-angiotensin system (RAS)
Danish: Begrænsning for kombineret anvendelse af lægemidler med virkning på renin-angiotensinsystemet (RAS)
English: The product information for all RAS-acting agents has been amended accordingly.
Danish: Produktinformationen for alle RAS-aktive midler er blevet rettet i henhold hertil.
English: • In a small number of patients (mostly with heart failure) there may still be a medical need to combine two classes of these medicines.
Danish: • Hos nogle få patienter (hovedsagelig med hjertesvigt) kan der fortsat være behov for at kombinere to forskellige klasser af disse lægemidler.
English: • RAS-acting agents from two different classes have sometimes been combined for an increased effect.
Danish: • Undertiden er RAS-aktive stoffer i to forskellige klasser blevet anvendt i kombination for at opnå større virkning.
English: This broad review of evidence relating to all RAS-acting agents supported the conclusions of a previous EMA review relating specifically to medicines containing aliskiren.1
Danish: Denne brede gennemgang af dokumentationen for alle RAS-aktive stoffer støttede konklusionerne af en EMA's tidligere gennemgang, der særligt vedrørte lægemidler indeholdende aliskiren.1
English: As some RAS-acting agents have been centrally authorised, the PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's final opinion.
Danish: Eftersom nogle RAS-aktive lægemidler er godkendt centralt, blev PRAC's anbefalinger overgivet til Udvalget for Lægemidler til Mennesker (CHMP), som har ansvar for alle spørgsmål vedrørende lægemidler til mennesker, og som vedtog agenturets endelige udtalelse.
English: They are used to treat conditions like high blood pressure or heart failure (when the heart cannot pump blood around the body as well as it should).
Danish: De anvendes til behandling af sygdomme såsom forhøjet blodtryk eller hjertesvigt (hvor hjertet ikke kan pumpe blodet rundt omkring i kroppen så godt som det skal).
English: These recommendations are based on a detailed review of the available data, including clinical trials, meta-analyses and publications, as well as advice from a group of experts on cardiovascular medicine.
Danish: Disse anbefalinger bygger på en detaljeret gennemgang af de foreliggende data, herunder kliniske undersøgelser, metaanalyser og publikationer, samt rådgivning fra en gruppe af eksperter i kardiovaskulær medicin.
English: RAS-acting agents have been authorised in the European Union (EU) through central and national approval procedures and are widely available in the EU under a variety of trade names.
Danish: RAS-aktive stoffer er godkendt i EU ved centrale og nationale godkendelsesprocedurer og fås i hele i EU under en række forskellige handelsnavne.
English: This is of particular concern, as these patients and patients with renal impairment are already prone to developing hyperkalaemia.
Danish: Dette er særlig betænkeligt, fordi disse patienter og patienter med nedsat nyrefunktion i forvejen har tendens til at få hyperkaliæmi.
English: • Available efficacy data indicate that such dual blockade does not provide significant benefit in the general patient population, although some selected patient sub-populations may possibly benefit.
Danish: • De foreliggende data om virkning tyder på, at sådan dobbelt blokering ikke indebærer nævneværdige fordele for den generelle patientpopulation, skønt visse udvalgte delpopulationer af patienter muligvis kan have fordel deraf.
English: The CHMP opinion was forwarded to the European Commission, which issued final decisions valid throughout the EU in September 2014.
Danish: CHMP's udtalelse blev overgivet til Europa-Kommissionen, som vedtog en beslutning med gyldighed i hele EU i september 2014.
English: The CHMP opinion was then forwarded to the European Commission, which confirmed it and issued final decisions, valid throughout the EU, on 4 and 9 September 2014.
Danish: CHMP's udtalelse blev derefter overgivet til Europa-Kommissionen, som bekræftede den og den 4. og 9. september 2014 vedtog endelige beslutninger med gyldighed i hele EU.
English: RAS-acting agents work by blocking different stages of the renin-angiotensin system (RAS).
Danish: RAS-aktive lægemidler virker ved at blokere forskellige trin i renin-angiotensin-systemet (RAS).
English: The CHMP opinion confirmed recommendations made by the Agency's Pharmacovigilance Risk Assessment Committee (PRAC) in April 2014, following assessment of evidence from several large studies in patients with various pre-existing heart and circulatory disorders, or with type 2 diabetes.
Danish: CHMP's udtalelse bekræftede anbefalingerne fra agenturets Udvalg for Risikovurdering inden for Lægemiddelvurdering (PRAC) fra april 2014, der efterfulgte en vurdering af dokumentationen fra flere store undersøgelser hos patienter, der i forvejen havde forskellige hjerte- og kredsløbsforstyrrelser eller type 2-sukkersyge.
English: In patients with heart failure there is some evidence that the addition of a second RAS-acting agent may reduce hospital admissions.
Danish: Hos patienter med hjerteinsufficiens er der nogen evidens for, at tilføjelse af endnu et RAS-aktivt middel kan nedsætte antallet af indlæggelser.
English: On 23 May 2014 the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) endorsed restrictions on combining different classes of medicines that act on the reninangiotensin system (RAS), a hormone system that controls blood pressure and the volume of fluids in the body.
Danish: Den 23. maj 2014 godkendte Det Europæiske Lægemiddelagenturs Udvalg for Lægemidler til Mennesker (CHMP) begrænsninger for kombination af forskellige klasser af lægemidler med virkning på renin-angiotensin-systemet (RAS), der er et hormonsystem, som regulerer blodtryk og væskevolumen i kroppen.
English: However, in patients with chronic heart failure, dual blockade should be limited to those intolerant to mineralocorticoid antagonists and with persistent symptoms despite other optimal therapy.
Danish: Hos patienter med kronisk hjerteinsufficiens bør dobbelt blokering imidlertid begrænses til patienter, der ikke tåler mineralokortikoidantagonister og har persisterende symptomer trods anden optimal terapi.
English: However, a review of the latest evidence has suggested that in most patients such combination does not increase the benefits, and may increase the risks of low blood pressure, increased potassium in the blood and possible damage to the kidney.
Danish: En gennemgang af den nyeste dokumentation har imidlertid peget på, at en sådan kombination hos de fleste patienter ikke giver øget fordel, men kan øge risikoen for lavt blodtryk, forhøjet kalium i blodet og muligvis nyreskade.
English: Furthermore, no significant benefits from dual blockade were seen in patients without heart failure and benefits were thought to outweigh risk only in a selected group of patients with heart failure in whom other treatments were unsuitable.
Danish: Desuden kunne der ikke konstateres nævneværdig fordel ved dobbelt blokering hos patienter uden hjertesvigt, og fordelene fandtes kun at opveje risiciene hos en udvalgt patientgruppe med hjertesvigt, der var uegnede for andre behandlinger.
English: Blocking the action of this hormone allows blood vessels to widen and helps to reduce the amount of water reabsorbed by the kidneys, thereby reducing blood pressure in the body.
Danish: Blokering af dette hormon får blodkarrene til at udvide sig og nedsætter mængden af vand, der tilbageabsorberes i nyrerne, hvorved blodtrykket sænkes.
English: • Combining RAS-acting agents is therefore no longer recommended.
Danish: • Derfor frarådes det nu at kombinere RAS-aktive stoffer.
English: The combination of aliskiren with an ARB or ACE-inhibitor is strictly contraindicated in those with kidney impairment or diabetes.
Danish: Kombination af aliskiren med en ARB eller en ACE-hæmmer er strengt kontraindiceret ved nyreinsufficiens eller diabetes.
English: ACE-inhibitors (benazepril, captopril, cilazapril, delapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril or zofenopril) and the direct renin inhibitor aliskiren block the actions of specific enzymes involved in the production of angiotensin II in the body (ACE-inhibitors block angiotensin-converting enzyme, while renin inhibitors block an enzyme called renin).
Danish: ACE-hæmmere (benazepril, captopril, cilazapril, delapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril eller zofenopril) og den direkte reninhæmmer aliskiren blokerer virkningen af særlige enzymer, der medvirker ved produktionen af angiotensin II i kroppen (ACE-hæmmere blokerer angiotensinkonverterende enzym, mens reninhæmmere blokerer enzymet renin).
English: • RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Danish: • RAS-aktive lægemidler virker ved at påvirke det hormonsystem, der regulerer blodtrykket og væskemængden i kroppen.
English: ARBs (containing the active substances azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan) block receptors for a hormone called angiotensin II.
Danish: ARB-lægemidler (indeholdende de aktive stoffer azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan eller valsartan) blokerer receptorerne for hormonet angiotensin II.
English: These studies found that combination of an ARB with an ACE-inhibitor was associated with an increased risk of hyperkalaemia (increased potassium in the blood), kidney damage or low blood pressure compared with using either medicine alone.
Danish: Disse undersøgelser viste, at kombination af en ARB med en ACE-hæmmer var forbundet med øget risiko for forhøjet kaliumindhold i blodets (hyperkaliæmi), nyrebeskadigelse eller for lavt blodtryk, sammenlignet med anvendelse af hvert lægemiddel for sig.
English: • In individual cases where combined use of an ARB and ACE inhibitor is considered absolutely essential, it must be carried out under specialist supervision with close monitoring of renal function, electrolytes and blood pressure.
Danish: • I enkeltstående tilfælde, hvor kombineret brug af en ARB og en ACE-hæmmer anses for absolut nødvendig, skal det ske under tilsyn af speciallæge og tæt overvågning af nyrefunktion, elektrolytter og blodtryk.
English: In particular, ACE-inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy, and existing contraindications on the use of aliskiren with either an ARB or an ACE inhibitor in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 ml/min/1.73 m2) are confirmed.
Danish: Navnlig bør ACE-hæmmere og ARB ikke anvendes sideløbende hos patienter med diabetisk nefropati, og de eksisterende kontraindikationer bekræftes for anvendelse af aliskiren sammen med enten en ARB eller en ACE-hæmmer hos patienter med diabetes mellitus eller moderat til svær nyreinsufficiens (GFR < 60 ml/min/1,73 m2).
English: This would include the licensed use of the ARBs candesartan or valsartan as addon therapy to ACE-inhibitors in patients with heart failure who require such a combination.
Danish: Hertil hører godkendt anvendelse af ARB-lægemidlerne candesartan eller valsartan som tillægsbehandling til ACE-hæmmere hos patienter med hjerteinsufficiens, der behøver en sådan kombination.
English: These medicines (called RAS-acting agents) belong to three main classes: angiotensin-receptor blockers (ARBs, sometimes known as sartans), angiotensin-converting enzyme inhibitors (ACEinhibitors) and direct renin inhibitors such as aliskiren.
Danish: Disse lægemidler (såkaldte RAS-aktive stoffer) kan inddeles i tre hovedklasser: angiotensinreceptorantagonister (ARB, undertiden betegnet sartan), angiotensinkonverterende enzym hæmmere (ACEhæmmere) og direkte reninhæmmere såsom aliskiren.
English: When this is considered absolutely necessary, it will be carried out under specialist supervision with close monitoring of kidney function, fluid and salt balance and blood pressure.
Danish: Når dette anses for absolut nødvendigt, skal det ske under tilsyn af speciallæge og tæt overvågning af nyrefunktion, væske- og saltbalance samt blodtryk.
English: In particular, patients who have kidney problems related to diabetes should not be given an ARB with an ACE inhibitor (use of either of these types of medicine with aliskiren is already prohibited in patients with diabetes or kidney problems).
Danish: Navnlig må patienter med sukkersygebetingede nyreproblemer ikke få en ARB i kombination med en ACE-hæmmer (anvendelse af en af disse typer lægemidler sammen med aliskiren er i forvejen forbudt til patienter med sukkersyge eller nyreproblemer).
English: • Such supervised use would include the licensed use of candesartan or valsartan as add-on therapy to ACE inhibitors in patients with heart failure.
Danish: • Sådant tilsyn bør ligeledes finde sted ved den godkendte anvendelse af candesartan eller valsartan som tillægsbehandling til ACE-hæmmere hos patienter med hjerteinsufficiens.
English: Where combination of these medicines (dual blockade) is considered absolutely necessary, it must be carried out under specialist supervision with close monitoring of kidney function, fluid and salt balance and blood pressure.
Danish: Når det anses for absolut nødvendigt at kombinere sådanne lægemidler (dobbelt blokering), skal det ske under tilsyn af speciallæge og tæt overvågning af nyrefunktion, væske- og saltbalance samt blodtryk.
English: These medicines can be of three different classes known as ARBs, ACE inhibitors and direct renin inhibitors (the last represented by the medicine aliskiren).
Danish: Disse lægemidler kan inddeles i tre forskellige klasser: ARB, ACE-hæmmere og direkte reninhæmmere (aliskiren hører til de sidstnævnte).
English: • The existing contraindication on the concomitant use of ACE-inhibitors or ARBs with aliskirencontaining products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2), which is based on the ALTITUDE study data, was confirmed in the light of the additional data reviewed.
Danish: • De gennemgåede supplerende data bekræftede den eksisterende kontraindikation af samtidig brug af ACE-hæmmere eller ARB sammen med aliskiren-holdige produkter hos patienter med diabetes mellitus eller nyreinsufficiens (GFR < 60 ml/min/1,73 m2), som bygger på data fra ALTITUDEundersøgelsen.
English: Combination of medicines from any two of these classes is not recommended and, in particular, patients with diabetes-related kidney problems (diabetic nephropathy) should not be given an ARB with an ACE-inhibitor.
Danish: Kombination af lægemidler tilhørende et vilkårligt par af disse klasser frarådes; navnlig bør ARB-lægemidler ikke kombineres med ACEhæmmere til patienter med sukkersygebetingede nyreproblemer (diabetisk nefropati).
English: • On the basis of current evidence, dual RAS blockade therapy through the combined use of ACEinhibitors, ARBs or aliskiren is not recommended in any patient.
Danish: • Dobbelt RAS-blokering gennem kombineret brug af ACE-hæmmere, ARB eller aliskiren frarådes hos alle patienter baseret på den aktuelt foreliggende evidens.
English: • There is considerable evidence from large clinical trials such as ONTARGET1, ALTITUDE2 and VA NEPHRON-D3 and from meta-analyses such as that of Makani4 (involving over 68,000 patients) demonstrating that dual RAS blockade through the combined use of ACE-inhibitors, ARBs or aliskiren is associated with an increased risk of adverse events, including hypotension, hyperkalaemia and renal failure compared with monotherapy, in particular in patients with diabetic nephropathy.
Danish: Makani4 (med over 68 000 patienter), som viser, at dobbelt RAS-blokering gennem kombineret brug af ACE-hæmmere, ARB eller aliskiren er forbundet med større risiko end monoterapi for bivirkninger, herunder hypotension, hyperkaliæmi og nyresvigt, navnlig hos patienter med diabetisk nefropati.
English: Shake vigorously at least 20 times before use.
Danish: Omrystes kraftigt mindst 20 gange før brug.
English: Date of first authorisation: 08/09/2015
Danish: Dato for første markedsføringstilladelse: 08/09/2015
English: The active substance in Novaquin is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Danish: Det aktive stof i Novaquin er et godkendt stof som beskrevet i tabel 1 i bilag til Kommissionens forordning (EU) Nr. 37/2010:
English: Pregnancy and lactation: See section “Contraindications”.
Danish: Drægtighed og laktation Se afsnittet 'Kontraindikationer'.
English: The major metabolites found in all species were the 5-hydroxyand 5-carboxy-metabolites and the oxalyl-metabolite.
Danish: Hovedmetabolitterne, som blev fundet i alle species var 5-hydroxy- og 5- carboxy-metabolitter samt oxalyl-metabolitten.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Danish: Hyppigheden af bivirkninger er defineret som: - Meget almindelig (flere end 1 ud af 10 behandlede dyr, der viser bivirkninger i løbet af en behandling) - Almindelige (flere end 1, men færre end 10 dyr ud af 100 behandlede dyr) - Ualmindelige (flere end 1, men færre end 10 dyr ud af 1.000 behandlede dyr) - Sjældne (flere end 1, men færre end 10 dyr ud af 10.000 behandlede dyr) - Meget sjælden (færre end 1 dyr ud af 10.000 behandlede dyr, herunder isolerede rapporter).
English: Approximately 98 % of meloxicam is bound to plasma proteins.
Danish: Distribution Omkring 98 % af meloxicam i plasma er proteinbundet.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Danish: Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu